Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future

Metabolomics and lipidomics are emerging methods for detailed phenotyping of small molecules in samples. It is hoped that such data will: (i) enhance baseline prediction of patient response to pharmacotherapies (beneficial or adverse); (ii) reveal changes in metabolites shortly after initiation of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rankin, Naomi J, Preiss, David, Welsh, Paul, Sattar, Naveed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100629/
https://www.ncbi.nlm.nih.gov/pubmed/27789671
http://dx.doi.org/10.1093/ije/dyw271
_version_ 1782466179661561856
author Rankin, Naomi J
Preiss, David
Welsh, Paul
Sattar, Naveed
author_facet Rankin, Naomi J
Preiss, David
Welsh, Paul
Sattar, Naveed
author_sort Rankin, Naomi J
collection PubMed
description Metabolomics and lipidomics are emerging methods for detailed phenotyping of small molecules in samples. It is hoped that such data will: (i) enhance baseline prediction of patient response to pharmacotherapies (beneficial or adverse); (ii) reveal changes in metabolites shortly after initiation of therapy that may predict patient response, including adverse effects, before routine biomarkers are altered; and( iii) give new insights into mechanisms of drug action, particularly where the results of a trial of a new agent were unexpected, and thus help future drug development. In these ways, metabolomics could enhance research findings from intervention studies. This narrative review provides an overview of metabolomics and lipidomics in early clinical intervention studies for investigation of mechanisms of drug action and prediction of drug response (both desired and undesired). We highlight early examples from drug intervention studies associated with cardiometabolic disease. Despite the strengths of such studies, particularly the use of state-of-the-art technologies and advanced statistical methods, currently published studies in the metabolomics arena are largely underpowered and should be considered as hypothesis-generating. In order for metabolomics to meaningfully improve stratified medicine approaches to patient treatment, there is a need for higher quality studies, with better exploitation of biobanks from randomized clinical trials i.e. with large sample size, adjudicated outcomes, standardized procedures, validation cohorts, comparison witth routine biochemistry and both active and control/placebo arms. On the basis of this review, and based on our research experience using clinically established biomarkers, we propose steps to more speedily advance this area of research towards potential clinical impact.
format Online
Article
Text
id pubmed-5100629
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-51006292016-11-10 Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future Rankin, Naomi J Preiss, David Welsh, Paul Sattar, Naveed Int J Epidemiol Reviews Metabolomics and lipidomics are emerging methods for detailed phenotyping of small molecules in samples. It is hoped that such data will: (i) enhance baseline prediction of patient response to pharmacotherapies (beneficial or adverse); (ii) reveal changes in metabolites shortly after initiation of therapy that may predict patient response, including adverse effects, before routine biomarkers are altered; and( iii) give new insights into mechanisms of drug action, particularly where the results of a trial of a new agent were unexpected, and thus help future drug development. In these ways, metabolomics could enhance research findings from intervention studies. This narrative review provides an overview of metabolomics and lipidomics in early clinical intervention studies for investigation of mechanisms of drug action and prediction of drug response (both desired and undesired). We highlight early examples from drug intervention studies associated with cardiometabolic disease. Despite the strengths of such studies, particularly the use of state-of-the-art technologies and advanced statistical methods, currently published studies in the metabolomics arena are largely underpowered and should be considered as hypothesis-generating. In order for metabolomics to meaningfully improve stratified medicine approaches to patient treatment, there is a need for higher quality studies, with better exploitation of biobanks from randomized clinical trials i.e. with large sample size, adjudicated outcomes, standardized procedures, validation cohorts, comparison witth routine biochemistry and both active and control/placebo arms. On the basis of this review, and based on our research experience using clinically established biomarkers, we propose steps to more speedily advance this area of research towards potential clinical impact. Oxford University Press 2016-10 2016-10-27 /pmc/articles/PMC5100629/ /pubmed/27789671 http://dx.doi.org/10.1093/ije/dyw271 Text en © The Author 2016; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Rankin, Naomi J
Preiss, David
Welsh, Paul
Sattar, Naveed
Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future
title Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future
title_full Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future
title_fullStr Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future
title_full_unstemmed Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future
title_short Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future
title_sort applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100629/
https://www.ncbi.nlm.nih.gov/pubmed/27789671
http://dx.doi.org/10.1093/ije/dyw271
work_keys_str_mv AT rankinnaomij applyingmetabolomicstocardiometabolicinterventionstudiesandtrialspastexperiencesandaroadmapforthefuture
AT preissdavid applyingmetabolomicstocardiometabolicinterventionstudiesandtrialspastexperiencesandaroadmapforthefuture
AT welshpaul applyingmetabolomicstocardiometabolicinterventionstudiesandtrialspastexperiencesandaroadmapforthefuture
AT sattarnaveed applyingmetabolomicstocardiometabolicinterventionstudiesandtrialspastexperiencesandaroadmapforthefuture